PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 107 filers reported holding PARATEK PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 4.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $27,000 | -37.2% | 14,050 | -3.4% | 0.04% | +24.1% |
| Q1 2022 | $43,000 | -44.2% | 14,550 | -6.4% | 0.03% | +31.8% |
| Q3 2021 | $77,000 | -39.4% | 15,550 | -20.5% | 0.02% | -57.7% |
| Q2 2021 | $127,000 | -8.0% | 19,550 | 0.0% | 0.05% | +20.9% |
| Q1 2021 | $138,000 | 0.0% | 19,550 | -11.3% | 0.04% | -27.1% |
| Q4 2020 | $138,000 | +1.5% | 22,050 | -10.2% | 0.06% | -3.3% |
| Q3 2020 | $136,000 | +4.6% | 24,550 | -2.0% | 0.06% | +10.9% |
| Q2 2020 | $130,000 | +66.7% | 25,050 | 0.0% | 0.06% | +57.1% |
| Q1 2020 | $78,000 | -22.0% | 25,050 | 0.0% | 0.04% | -2.8% |
| Q4 2019 | $100,000 | -6.5% | 25,050 | 0.0% | 0.04% | -16.3% |
| Q3 2019 | $107,000 | -10.1% | 25,050 | -16.6% | 0.04% | -20.4% |
| Q2 2019 | $119,000 | -16.2% | 30,050 | +13.1% | 0.05% | -41.3% |
| Q1 2019 | $142,000 | -11.2% | 26,567 | +8.7% | 0.09% | +17.9% |
| Q4 2018 | $160,000 | +39.1% | 24,450 | +81.8% | 0.08% | +25.8% |
| Q3 2018 | $115,000 | – | 13,450 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $36,172,000 | 26.83% |
| Abingworth LLP | 1,301,413 | $18,103,000 | 18.96% |
| Roumell Asset Management, LLC | 290,136 | $4,036,000 | 9.16% |
| Monashee Investment Management LLC | 100,000 | $1,391,000 | 2.19% |
| BVF INC/IL | 575,000 | $7,998,000 | 1.70% |
| Aisling Capital LLC | 482,680 | $6,714,000 | 1.59% |
| Opaleye Management Inc. | 146,700 | $2,041,000 | 1.36% |
| Broadfin Capital, LLC | 803,332 | $11,174,000 | 1.09% |
| GENERAL AMERICAN INVESTORS CO INC | 477,076 | $6,636,000 | 0.69% |
| Opus Point Partners Management, LLC | 37,665 | $524,000 | 0.51% |